Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: Subanalysis of the CHAMPION study

British Journal of Dermatology

Volumn 165, Issue 2, 2011, Pages 399-406

  Saurat, J H ^a   Langley, R G ^b   Reich, K ^c   Unnebrink, K ^d   Sasso, E H ^e   Kampman, W ^f  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Dermatologikum Hamburg   (Germany)

^d ABBOTT GMBH AND CO KG   (Germany)

^e ABBOTT LABORATORIES   (United States)

^f ABBOTT LABORATORIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE ACTIVITY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HEPATITIS; HERPES SIMPLEX; HUMAN; HYPERTENSION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; OPTIC NEURITIS; PATIENT COMPLIANCE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; SIDE EFFECT; SORE THROAT; STOMACH PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS INFECTION;

ADULT; AGED; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79960638164     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10399.x     Document Type: Article

References (23)

1. Edmundson WF, Guy WB,. Treatment of psoriasis with folic acid antagonists. AMA Arch Derm 1958; 78: 200-3.
2. Smith KC,. Systemic therapy of psoriasis using methotrexate. Skin Therapy Lett 2000; 6: 1-2.
3. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-65. (Pubitemid 36975998)
4. Flytstrom I, Stenberg B, Svensson A, et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116-21. (Pubitemid 350221914)
5. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66. (Pubitemid 351239154)
6. Reich K, Pohl C, Wozel G, et al. Infliximab is associated with greater improvement in health-related quality of life versus methotrexate for moderate-to-severe plaque-type psoriasis-the Restore 1 trial. Presented at the 18th Congress of the European Academy of Dermatology and Venereology, October 7-11, 2009; Berlin, Germany. Abstract P1187.
7. Reich K, Langley RG, Papp K, et al. Efficacy and safety of briakinumab (ABT-874) versus methotrexate in patients with moderate to severe psoriasis. Presented at the 19th Congress of the European Academy of Dermatology and Venereology, October 6-10, 2010; Gothenburg, Sweden. Abstract P555.
8. Hroch M, Chladek J, Simkova M, et al. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol 2008; 22: 19-24.
9. Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-37.
10. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-85.
11. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
12. Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-38. (Pubitemid 46835379)
13. Chladek J, Martinkova J, Simkova M, et al. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 1998; 53: 437-44. (Pubitemid 28154744)
14. Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP,. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011; 63: 359-64.
15. Dervieux T, Orentas Lein D, Marcelletti J, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 2003; 49: 1632-41. (Pubitemid 37194217)
16. Dervieux T, Wessels JA, van der Straaten T, et al. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics 2009; 19: 935-44.
17. Warren RB, Smith RL, Campalani E, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009; 160: 438-41.
18. Warren RB, Smith RL, Campalani E, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008; 128: 1925-9. (Pubitemid 352001201)
19. Griffiths CEM, Clark CM, Chalmers RJG, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1-125.
20. Leon A, Nguyen A, Letsinger J, Koo J,. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. Expert Opin Pharmacother 2007; 8: 617-32. (Pubitemid 46547015)
21. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-26.
22. Sitzo S, Bansback N, Feldman SR, et al. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009; 160: 1264-72.
23. Kuhn A, Ruland V, Patsinakidis N, Luger TA,. Use of methotrexate in patients with psoriasis. Clin Exp Rheumatol 2010; 28 (Suppl. 61): S138-44.